Biocon Shares Price
-
{
- All
- News
-
Biocon Declines Over 3% After Net Profit Increased 105% In March Quarter
Biocon Share Price Today: On Friday, Biocon opened on the BSE at Rs 392, touching an intra day high of Rs 392 and an intra day low of Rs 380.55, in the trading session so far.
-
Biocon Declines Over 3% After Net Profit Increased 105% In March Quarter
Biocon Share Price Today: On Friday, Biocon opened on the BSE at Rs 392, touching an intra day high of Rs 392 and an intra day low of Rs 380.55, in the trading session so far.
-
Biocon To Buy 26% Stake In Hinduja Renewables Two
"The cost of the acquisition is Rs 5,91,61,730 for the acquisition of 26 per cent stake on a fully diluted basis in one or more tranches," the Bangalore-based Biocon said in a BSE filing.
-
Biocon Soars Nearly 10% On Receiving Nod For Covid-19 Drug
Biocon Share: Biocon received approval from the Drugs Controller General of India to market its novel biologic drug Itolizumab for treating patients having Covid-19 complications.
-
Biocon Shares Fall After Profit Declines In December Quarter
On a standalone basis, Biocon's profit plunged 72 per cent annually to Rs 33 crore from Rs 121 crore during the same period last year.
-
Biocon Declines Over 3% After Net Profit Increased 105% In March Quarter
Biocon Share Price Today: On Friday, Biocon opened on the BSE at Rs 392, touching an intra day high of Rs 392 and an intra day low of Rs 380.55, in the trading session so far.
-
Biocon Shares Fall After Profit Declines In December Quarter
On a standalone basis, Biocon's profit plunged 72 per cent annually to Rs 33 crore from Rs 121 crore during the same period last year.
-
Biocon To Buy 26% Stake In Hinduja Renewables Two
"The cost of the acquisition is Rs 5,91,61,730 for the acquisition of 26 per cent stake on a fully diluted basis in one or more tranches," the Bangalore-based Biocon said in a BSE filing.
-
Biocon Soars Nearly 10% On Receiving Nod For Covid-19 Drug
Biocon Share: Biocon received approval from the Drugs Controller General of India to market its novel biologic drug Itolizumab for treating patients having Covid-19 complications.
-
Biocon Declines Over 3% After Net Profit Increased 105% In March Quarter
Biocon Share Price Today: On Friday, Biocon opened on the BSE at Rs 392, touching an intra day high of Rs 392 and an intra day low of Rs 380.55, in the trading session so far.
-
Biocon Declines Over 3% After Net Profit Increased 105% In March Quarter
Biocon Share Price Today: On Friday, Biocon opened on the BSE at Rs 392, touching an intra day high of Rs 392 and an intra day low of Rs 380.55, in the trading session so far.
-
Biocon To Buy 26% Stake In Hinduja Renewables Two
"The cost of the acquisition is Rs 5,91,61,730 for the acquisition of 26 per cent stake on a fully diluted basis in one or more tranches," the Bangalore-based Biocon said in a BSE filing.
-
Biocon Soars Nearly 10% On Receiving Nod For Covid-19 Drug
Biocon Share: Biocon received approval from the Drugs Controller General of India to market its novel biologic drug Itolizumab for treating patients having Covid-19 complications.
-
Biocon Shares Fall After Profit Declines In December Quarter
On a standalone basis, Biocon's profit plunged 72 per cent annually to Rs 33 crore from Rs 121 crore during the same period last year.
-
Biocon Declines Over 3% After Net Profit Increased 105% In March Quarter
Biocon Share Price Today: On Friday, Biocon opened on the BSE at Rs 392, touching an intra day high of Rs 392 and an intra day low of Rs 380.55, in the trading session so far.
-
Biocon Shares Fall After Profit Declines In December Quarter
On a standalone basis, Biocon's profit plunged 72 per cent annually to Rs 33 crore from Rs 121 crore during the same period last year.
-
Biocon To Buy 26% Stake In Hinduja Renewables Two
"The cost of the acquisition is Rs 5,91,61,730 for the acquisition of 26 per cent stake on a fully diluted basis in one or more tranches," the Bangalore-based Biocon said in a BSE filing.
-
Biocon Soars Nearly 10% On Receiving Nod For Covid-19 Drug
Biocon Share: Biocon received approval from the Drugs Controller General of India to market its novel biologic drug Itolizumab for treating patients having Covid-19 complications.
